• Center on Health Equity & Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Segment 11 - Why It Is an Exciting Time for Immuno-Oncology

Article

The panelists offer their closing remarks regarding immuno-oncology's promises and challenges.

The panelists offer their closing remarks regarding immuno-oncology’s promises and challenges.

Jianda Yuan, MD, PhD, explains why this is an exciting time for immunotherapy, and Kimberly Shafer-Weaver, PhD, added that discussing immuno-oncology early on is important so that the best decisions can be made for not only patients, but also the payers.

“Sometimes, it is tempting, I think, to get discouraged that the innovations that we are seeing are going to come at a price tag that we cannot afford,” Michael Kolodziej, MD, added in conclusion. “I think that is a mistake. I think that what we should be focused on is really finding out how much these innovations truly add to what we are doing now and who benefits the most.”

Related Videos
Screenshot of Adam Colborn, JD during an interview
Wanmei Ou, PhD, vice president of product, data analytics, and AI at Ontada
Glenn Balasky, executive director of the Rocky Mountain Cancer Center.
Corey McEwen, PharmD, MS
dr linda bosserman
dr andrew leitner
Glenn Balasky during a video interview
Related Content
© 2024 MJH Life Sciences
AJMC®
All rights reserved.